Drug Pricing Reform Without Innovation Backlash? ICER Aims To Find The Path
Executive Summary
With new report looking at price increases rather than launch prices, ICER hopes to show it's possible to set limits without negatively impacting development of medicines. Report takes aim at some common drug industry arguments against price reforms and shows some net prices increasing faster than list prices, making it harder for pharma to divert blame to supply chain.